参考文献
参考文献
1. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. Int J Gynaecol Obstet. 2020 Jun;149(3):273-86.全文 摘要
2. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2021 Mar 12:70(10);355-61.全文 摘要
3. Delahoy MJ, Whitaker M, O’Halloran A, et al. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19 — COVID-NET, 13 states, March 1–August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 25;69(38):1347-54.全文 摘要
4. International Federation of Gynecology and Obstetrics. Safe motherhood and COVID-19 – March 2021 update. 2021 [internet publication].全文
5. Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: a national retrospective cohort study. PLoS Med. 2021 Nov 30;18(11):e1003857.全文 摘要
6. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep 2020 Jun 26;69(25):769-75.全文
7. Royal College of Midwives and Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection and pregnancy. Mar 2022 [internet publication].全文
8. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020 Jun 8;369:m2107.全文 摘要
9. Ahlberg M, Neovius M, Saltvedt S, et al. Association of SARS-CoV-2 test status and pregnancy outcomes. JAMA. 2020 Sep 23;324(17):1782-5.全文 摘要
10. Woodworth KR, Olsen EO, Neelam V, et al. Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy - SET-NET, 16 jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1635-40.全文 摘要
11. Jering KS, Claggett BL, Cunningham JW, et al. Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19. JAMA Intern Med. 2021 May 1;181(5):714-7.全文 摘要
12. Gurol-Urganci I, Jardine JE, Carroll F, et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol. 2021 Nov;225(5):522.e1-522.e11.全文 摘要
13. Piekos SN, Roper RT, Hwang YM, et al. The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study. Lancet Digit Health. 2022 Jan 13;4(2):e95-104.全文 摘要
14. Marchand G, Patil AS, Masoud AT, et al. Systematic review and meta-analysis of COVID maternal and neonatal clinical features and pregnancy outcomes to June 3rd 2021. AJOG Glob Rep. 2022 Feb;2(1):100049.全文 摘要
15. Metz TD, Clifton RG, Hughes BL, et al. Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications. JAMA. 2022 Feb 22;327(8):748-59.全文 摘要
16. Ferrara A, Hedderson M, Zhu Y, et al. Perinatal complications in individuals in California with or without SARS-CoV-2 infection during pregnancy. JAMA Intern Med. 2022 May 1;182(5):503-12.全文 摘要
17. McClymont E, Albert AY, Alton GD, et al. Association of SARS-CoV-2 infection during pregnancy with maternal and perinatal outcomes. JAMA. 2 May 2022 [Epub ahead of print].全文 摘要
18. Panagiotakopoulos L, Myers TR, Gee J, et al. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics — eight U.S. health care centers, March 1–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23;69(38):1355-9.全文 摘要
19. Khoury R, Bernstein PS, Debolt C, et al. Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at five New York City medical centers. Obstet Gynecol. 2020 Aug;136(2):273-82.全文 摘要
20. Metz TD, Clifton RG, Hughes BL, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2021 Apr 1;137(4):571-80.全文 摘要
21. Flaherman VJ, Afshar Y, Boscardin J, et al. Infant outcomes following maternal infection with SARS-CoV-2: first report from the PRIORITY study. Clin Infect Dis. 2021 Nov 2;73(9):e2810-13.全文 摘要
22. Norman M, Navér L, Söderling J, et al. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. JAMA. 2021 May 25;325(20):2076-86.全文 摘要
23. DeSisto CL, Wallace BL, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-45.全文 摘要
24. Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. BMJ. 2022 Mar 16;376:e067696.全文 摘要
25. International Federation of Gynecology and Obstetrics. COVID-19 vaccination for pregnant and breastfeeding women. Mar 2021 [internet publication].全文
26. American College of Obstetricians and Gynecologists (ACOG). COVID-19 vaccination considerations for obstetric–gynecologic care. Jun 2022 [internet publication].全文
27. Centers for Disease Control and Prevention. Information about COVID-19 vaccines for people who are pregnant or breastfeeding. Mar 2022 [internet publication].全文
28. UK Health Security Agency. COVID-19: the green book, chapter 14a: Coronavirus (COVID-19) vaccination information for public health professionals. Feb 2022 [internet publication].全文
29. Prasad S, Kalafat E, Blakeway H, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022 May 10;13(1):2414.全文 摘要
30. Fell DB, Dhinsa T, Alton GD, et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA. 2022 Apr 19;327(15):1478-87.全文 摘要
31. Magnus MC, Örtqvist AK, Dahlqwist E, et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA. 2022 Apr 19;327(15):1469-77.全文 摘要
32. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021 Jun 17;384(24):2273-82.全文 摘要
33. Zauche L, Wallace B, Smoots AN, et al. Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion. N Engl J Med. 2021 Oct 14;385(16):1533-5.全文 摘要
34. Kharbanda EO, Haapala J, DeSilva M, et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA. 2021 Oct 26;326(16):1629-31.全文 摘要
35. Magnus MC, Gjessing HK, Eide HN. et al. Covid-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med. 2021 Nov 18;385(21):2008-10.全文 摘要
36. UK Health Security Agency. COVID-19 vaccine weekly surveillance reports (weeks 39 to 31). Aug 2022 [internet publication].全文
37. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):26-30.全文 摘要
38. Vousden N, Ramakrishnan R, Bunch K, et al. Severity of maternal infection and perinatal outcomes during periods of SARS-CoV-2 wildtype, alpha, and delta variant dominance in the UK: prospective cohort study. BMJ Medicine. 2022 Mar 9;1:e000053.全文
39. Adhikari EH, MacDonald L, SoRelle JA, et al. COVID-19 cases and disease severity in pregnancy and neonatal positivity associated with Delta (B.1.617.2) and Omicron (B.1.1.529) variant predominance. JAMA. 2022 Apr 19;327(15):1500-2.全文 摘要
40. DeSilva M, Haapala J, Vazquez-Benitez G, et al. Evaluation of acute adverse events after Covid-19 vaccination during pregnancy. N Engl J Med. 2022 Jul 14;387(2):187-9.全文 摘要
41. Hillson K, Costa Clemens S, Madhi SA, et al. Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. Lancet. 2021 Nov 6;398(10312):1683-4.全文 摘要
42. Aharon D, Lederman M, Ghofranian A, et al. In vitro fertilization and early pregnancy outcomes after coronavirus disease 2019 (COVID-19) vaccination. Obstet Gynecol. 25 Jan 2022 [Epub ahead of print].全文 摘要
43. Magee LA, von Dadelszen P, Kalafat E, et al. COVID-19 vaccination in pregnancy-number needed to vaccinate to avoid harm. Lancet Infect Dis. 2021 Dec;21(12):1627.全文 摘要
44. Gill L, Jones C. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in neonatal cord blood after vaccination in pregnancy. Obstet Gynecol. 2021 May 1;137(5):894-6.全文 摘要
45. Perl S, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2–specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA. 2021 May 18;325(19):2013-4.全文 摘要
46. Gray KJ, Bordt EA, Atyeo C, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021 Sep;225(3):303.全文 摘要
47. Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021 Jun 1;175(6):594-600.全文 摘要
48. Kugelman N, Nahshon C, Shaked-Mishan P, et al. Maternal and neonatal severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) immunoglobulin G levels after the Pfizer-BioNTech booster dose for Coronavirus disease 2019 (COVID-19) vaccination during the second trimester of pregnancy. Obstet Gynecol. 2022 Aug 1;140(2):187-93.全文 摘要
49. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of maternal vaccination with mRNA COVID-19 vaccine during pregnancy against COVID-19-associated hospitalization in infants aged <6 months - 17 states, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-70.全文 摘要
50. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med. 2022 Aug 1;182(8):825-31.全文 摘要
51. Halasa NB, Olson SM, Staat MA, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med. 2022 Jul 14;387(2):109-19.全文 摘要
52. American Academy of Pediatrics. FAQs: management of infants born to mothers with suspected or confirmed COVID-19. Dec 2021 [internet publication].全文
53. Salvatore CM, Han JY, Acker KP, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. Lancet Child Adolesc Health. 2020 Oct;4(10):721-7.全文 摘要
54. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. Oct 2020 [internet publication].全文 摘要
55. Ronchi A, Pietrasanta C, Zavattoni M, et al. Evaluation of rooming-in practice for neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection in Italy. JAMA Pediatr. 2021 Mar 1;175(3):260-6.全文 摘要
56. Resuscitation Council UK. COVID-19 resources: newborn life support. Sep 2021 [internet publication].全文
57. World Health Organization. Clinical management of COVID-19: living guidance. Nov 2021 [internet publication].全文
58. American College of Obstetricians and Gynecologists. COVID-19 FAQs for obstetrician-gynecologists, obstetrics. Mar 2022 [internet publication].全文
59. Centers for Disease Control and Prevention. Care for breastfeeding women. Interim guidance on breastfeeding and breast milk feeds in the context of COVID-19. Dec 2021 [internet publication].全文
60. Chambers C, Krogstad P, Bertrand K, et al. Evaluation for SARS-CoV-2 in breast milk from 18 infected women. JAMA. 2020 Oct 6;324(13):1347-8.全文 摘要
61. Anticoagulation Forum. Managing anticoagulation during the COVID-19 pandemic: frequently asked questions. Mar 2020 [internet publication].全文
62. Medicines and Healthcare Products Regulatory Agency. Warfarin and other anticoagulants - monitoring of patients during the COVID-19 pandemic. Oct 2020 [internet publication].全文
63. NHS National Patient Safety Alert. Inappropriate anticoagulation of patients with a mechanical heart valve. Jul 2021 [internet publication].全文
64. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines: antithrombotic therapy in patients with COVID-19. May 2022 [internet publication].全文
65. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. Jun 2022 [internet publication].全文
66. Speed V, Patel RK, Byrne R, et al. A perfect storm: root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic. Thromb Res. 2020 Aug;192:73-4.全文 摘要
67. Handy A, Banerjee A, Wood A, et al. Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort. Heart. 10 Mar 2022 [Epub ahead of print].全文 摘要
68. Lin L, Wang X, Ren J, et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ Open. 2020 Nov 10;10(11):e042573.全文 摘要
69. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. JAMA Netw Open. 2021 Mar 1;4(3):e211095.全文 摘要
70. Nephrology Journal Club. Acute kidney injury. Mar 2020 [internet publication].全文
71. Fair Health. Risk factors for COVID-19 mortality among privately insured patients: a claims data analysis. Nov 2020 [internet publication].全文
72. Zeidan AM, Boddu PC, Patnaik MM, et al. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug;7(8):e601-e612.全文 摘要
73. American Society of Hematology. COVID-19 and adult ALL: frequently asked questions. Jan 2021 [internet publication].全文
74. Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021 Aug;8(8):e583-92.全文 摘要
75. Sun C, Pleyer C, Wiestner A. COVID-19 vaccines for patients with haematological conditions. Lancet Haematol. 2021 May;8(5):e312-4.全文 摘要
76. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737-45.全文 摘要
77. National Cancer Research Institute Acute Myelogenous Leukaemia working party. Recommendations for the management of patients with AML during the COVID-19 outbreak. Oct 2020 [internet publication].全文
78. Arlt W, Baldeweg SE, Pearce SHS, et al. Endocrinology in the time of COVID-19: management of adrenal insufficiency. Eur J Endocrinol. 2020 Jul;183(1):G25-32.全文 摘要
79. American Society of Hematology. COVID-19 and aplastic anemia: frequently asked questions. May 2021 [internet publication].全文
80. European Society for Blood and Marrow Transplantation. COVID-19 - bone marrow failure and PNH recommendations on behalf of the Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation (EBMT). Mar 2020 [internet publication].全文
81. NHS England. Eltrombopag as bridging therapy to haematopoietic stem cell transplant in severe or very severe aplastic anaemia during the COVID19 pandemic (in adults) (RPS 2006). Dec 2021 [internet publication].全文
82. Pike A, McKinley C, Forrest B, et al. COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. Lancet Haematol. 2022 Aug;9(8):e553-6.全文 摘要
83. Cardinale F, Ciprandi G, Barberi S, et al. Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Ital J Pediatr. 2020 Jun 16;46(1):84.全文 摘要
84. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2022. [internet publication].全文
85. Licskai C, Yang CL, Ducharme FM, et al. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic. Can J Resp Crit Care Sleep Med. 2020 Apr 30;4(2):73-6.全文
86. European Lung Foundation. COVID-19 and lung disease Q&A. Mar 2021 [internet publication].全文
87. Centers for Disease Control and Prevention. Clinical questions about COVID-19: questions and answers. Jun 2022 [internet publication].全文
88. Virant FS, Randolph C, Nanda A, et al. Pulmonary procedures during the COVID-19 pandemic: a work group Report of the AAAAI Asthma Diagnosis and Treatment (ADT) interest section. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1474-84.全文 摘要
89. Elliott J, Bodinier B, Whitaker M, et al. COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors. Eur J Epidemiol. 2021 Mar;36(3):299-309.全文 摘要
90. American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Nov 2021 [internet publication].全文
91. Boettler T, Marjot T, Newsome PN, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020 Oct;2(5):100169.全文 摘要
92. British Society of Gastroenterology. A joint statement on vaccination for Sars-CoV-2 in patients with liver disease. Mar 2021 [internet publication].全文
93. Edmonds CE, Zuckerman SP, Conant EF. Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of coronavirus disease (COVID-19) vaccination. AJR Am J Roentgenol. 2021 Oct;217(4):831-4.全文 摘要
94. Robinson KA, Maimone S, Gococo-Benore DA, et al. Incidence of axillary adenopathy in breast imaging after COVID-19 vaccination. JAMA Oncol. 2021 Sep 1;7(9):1395-7.全文 摘要
95. Royal College of Paediatrics and Child Health. National guidance for the management of children with bronchiolitis and lower respiratory tract infections during COVID-19. May 2022 [internet publication].全文
96. International Liaison Committee on Resuscitation. COVID-19: practical guidance for implementation. 2020 [internet publication].全文
97. Resuscitation Council UK. Resuscitation Council UK statement on COVID-19 in relation to CPR and resuscitation in acute hospital settings. Aug 2021 [internet publication].全文
98. Hsu A, Sasson C, Kudenchuk PJ, et al. 2021 Interim guidance to health care providers for basic and advanced cardiac life support in adults, children, and neonates with suspected or confirmed COVID-19. Circ Cardiovasc Qual Outcomes. 2021 Oct;14(10):e008396.全文 摘要
99. Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J. 2022 Mar 14;43(11):1059-103.全文 摘要
100. Resuscitation of the drowned person in the era of COVID-19 disease: a common ground for recommendations, identification of research needs and a global call to action. Position Statement of the International Drowning Researchers' Alliance, International Life Saving Federation Medical Committee and International Maritime Rescue Federation. May 2020 [internet publication].全文
101. Position Statement: cardiopulmonary resuscitation of patients with confirmed or suspected COVID-19 - 2020. Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Society of Cardiology (SBC), Brazilian Association of Intensive Care Medicine (AMIB), and Brazilian Society of Anesthesiology (SBA). Jul 2020 [internet publication].全文
102. Carr EJ, Wu M, Harvey R, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021 Sep 18;398(10305):1038-41.全文 摘要
103. Sibbel S, McKeon K, Luo J, et al. Real-world effectiveness and immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV2 vaccines in patients on hemodialysis. J Am Soc Nephrol. 2022 Jan;33(1):49-57.全文 摘要
104. Hsu CM, Weiner DE, Manley HJ, et al. Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months. Clin J Am Soc Nephrol. 2022 Mar;17(3):403-13.全文 摘要
105. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021 Jun 10;137(23):3165-73.全文 摘要
106. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. Dec 2021 [internet publication].全文
107. Bloom C, Drake T, Docherty A, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):699-711.全文 摘要
108. British Thoracic Society. COPD and COVID-19 for healthcare professionals. Apr 2020 [internet publication].全文
109. British Thoracic Society. Pulmonary rehabilitation resource pack. Jun 2021 [internet publication].全文
110. Tan JY, Conceicao EP, Wee LE, et al. COVID-19 public health measures: a reduction in hospital admissions for COPD exacerbations. Thorax. 2021 May;76(5):512-3.全文 摘要
111. Große K, Kramer M, Trautwein C, et al. SARS-CoV-2 as an extrahepatic precipitator of acute-on-chronic liver failure. Liver Int. 2020 Jul;40(7):1792-3.全文 摘要
112. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010 May;85(5):451-8.全文 摘要
113. Marjot T, Webb GJ, Barritt AS, et al. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-8.全文 摘要
114. John BV, Deng Y, Scheinberg A, et al. Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med. 2021 Oct 1;181(10):1306-14.全文 摘要
115. US Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. Mar 2020 [internet publication].全文
116. Centers for Disease Control and Prevention. Fungal diseases and COVID-19. Mar 2022 [internet publication].全文
117. Alsaied T, Aboulhosn JA, Cotts TB, et al. Coronavirus disease 2019 (COVID-19) pandemic implications in pediatric and adult congenital heart disease. J Am Heart Assoc. 2020 Jun 16;9(12):e017224.全文 摘要
118. Diller GP, Gatzoulis MA, Broberg CS, et al. Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease. Eur Heart J. 2021 May 14;42(19):1858-65.全文 摘要
119. Ehwerhemuepha L, Roth B, Patel AK, et al. Association of congenital and acquired cardiovascular conditions with COVID-19 severity among pediatric patients in the US. JAMA Netw Open. 2022 May 2;5(5):e2211967.全文 摘要
120. Radke RM, Frenzel T, Baumgartner H, et al. Adult congenital heart disease and the COVID-19 pandemic. Heart. 2020;106:1302-09.全文
121. International Organization for the Study of Inflammatory Bowel Disease. Care of the IBD patient requiring hospitalization or surgery during the COVID-19 pandemic. May 2020 [internet publication].全文
122. International Organisation for the study of inflammatory bowel disease. IOIBD recommendations: best practice guidance for when to restart IBD therapy in patients who have suspected or confirmed COVID-19. May 2020 [internet publication].全文
123. Remzi FH, Panis Y, Spinelli A, et al. International Organization for the Study of Inflammatory Bowel Disease recommendations for surgery in patients with inflammatory bowel disease during the COVID-19 pandemic. Dis Colon Rectum. 2020 Jul;63(7):870-3.全文 摘要
124. British Society of Gastroenterology. BSG inflammatory bowel disease section and clinical research group position statement on SARS-CoV2 vaccination. Sep 2021 [internet publication].全文
125. Syversen SW, Jyssum I, Tveter AT, et al. Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients on immunosuppressive therapy. Arthritis Rheumatol. 4 May 2022 [Epub ahead of print].全文 摘要
126. Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-52.全文 摘要
127. Sperger J, Shah K, Lu M, et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. BMJ Open. 2021 Nov 12;11(11):e049740.全文 摘要
128. Newell-Price J, Nieman L, Reincke M, et al. Endocrinology in the time of COVID-19: Management of Cushing's syndrome. Eur J Endocrinol. 2020 Jul;183(1):G1-7.全文 摘要
129. Pivonello R, Ferrigno R, Isidori A, et al. COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. Lancet Diabetes Endocrinol. 2020 Aug;8(8):654-6.全文 摘要
130. Association of British Clinical Diabetologists. Concise advice on inpatient diabetes during COVID19 - front door guidance. Nov 2020 [internet publication].全文
131. Coppelli A, Giannarelli R, Aragona M, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes Care. 2020 Oct;43(10):2345-8.全文 摘要
132. Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care. 2021 Feb;44(2):578-85.全文 摘要
133. American Diabetes Association. COVID-19: if you do get sick, know what to do. Mar 2020 [internet publication].全文
134. Diabetes and Primary Care. At a glance fact sheet: COVID-19 and diabetes. Apr 2020 [internet publication].全文
135. Mackie SL, Brouwer E, Conway R, et al. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatol. 2021 Jan;3(1):e71-e82.全文 摘要
136. American College of Rheumatology. COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases (RMDs). Feb 2022.全文 摘要
137. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 23 Feb 2022 [Epub ahead of print].全文 摘要
138. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.全文 摘要
139. US Department of Health and Human Services. Guidance for COVID-19 and persons with HIV. Feb 2022 [internet publication].全文
140. European AIDS Clinical Society (EACS) and British HIV Association (BHIVA). EACS & BHIVA statement on risk of COVID-19 for people living with HIV (PLWH). Apr 2020 [internet publication].全文
141. European AIDS Clinical Society. COVID-19 and HIV. BHIVA, DAIG, EACS, GESIDA & Polish Scientific AIDS Society. Statement on risk of COVID-19 for people living with HIV (PLWH). May 2020 [internet publication].全文
142. Infectious Disease Society of America and HIV Medicine Association. COVID-19: special considerations for people living with HIV. Dec 2020 [internet publication].全文
143. Netto LC, Ibrahim KY, Picone CM, et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV. 2022 May;9(5):e323-e331.全文 摘要
144. Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med. 2021 Aug;9(8):909-23.全文 摘要
145. Canadian Thoracic Society. Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Aug 2020 [internet publication].全文
146. American Society for Hematology. COVID-19 and ITP: frequently asked questions. Apr 2021 [internet publication].全文
147. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. May 2022 [internet publication].全文
148. Sultan S, Altayar O, Siddique SM, et al. AGA Institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020 Jul;159(1):320-34.e27.全文 摘要
149. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;20(3):1-8.全文 摘要
150. John TM, Jacob CN, Kontoyiannis DP, et al. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel). 2021 Apr 15;7(4):298.全文 摘要
151. Joshi S, Telang R, Tambe M, et al. Outbreak of mucormycosis in coronavirus disease patients, Pune, India. Emerg Infect Dis. 2021 Sep 29;28(1).全文 摘要
152. Mejía-Santos H, Montoya S, Chacón-Fuentes R, et al. Notes from the field: mucormycosis cases during the COVID-19 pandemic - Honduras, May-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1747-9.全文 摘要
153. Dulski TM, DeLong M, Garner K, et al. Notes from the field: COVID-19-associated mucormycosis - Arkansas, July-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1750-1.全文 摘要
154. Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 4 Apr 2022 [Epub ahead of print].全文 摘要
155. Department of Health Research Ministry of Health and Family Welfare Government of India. Evidence based advisory in the time of Covid-19. Screening, diagnosis & management of mucormycosis. 2021 [internet publication].全文
156. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose. Blood. 2021 Jul 1;137(26):3674-6.全文 摘要
157. Ludwig H, Sonneveld P, Facon T, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021 Dec;8(12):e934-46.全文 摘要
158. Association of British Neurologists. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the COVID-19 pandemic. Nov 2020 [internet publication].全文
159. National Multiple Sclerosis Society. MS treatment guidelines during coronavirus. 2020 [internet publication].全文
160. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Jun 26;77(9):1-10.全文 摘要
161. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 Jun 1;78(6):699-708.全文 摘要
162. MS Society Medical Advisers consensus statement on MS treatments and COVID-19 vaccines. Jan 2022 [Internet publication].全文
163. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835.全文 摘要
164. Disanto G, Sacco R, Bernasconi E, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021 Dec 1;78(12):1529-31.全文 摘要
165. Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021 Dec 1;78(12):1510-4.全文 摘要
166. König M, Torgauten HM, Tran TT, et al. Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol. 2022 Mar 1;79(3):307-9.全文 摘要
167. Madelon N, Heikkilä N, Sabater Royo I, et al. Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2022 Apr 1;79(4):399-404.全文 摘要
168. Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021 Feb 1;7(2):220-7.全文 摘要
169. Di Ciaccio P, McCaughan G, Trotman J, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J. 2020 Jun;50(6):667-79.全文 摘要
170. Guidance for the management of patients with lymphoma during the COVID19 health emergency: a statement from a panel of UK lymphoma experts. Mar 2020 [internet publication].全文
171. American Society for Hematology. COVID-19 and aggressive lymphoma: frequently asked questions. Apr 2022 [internet publication].全文
172. Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020 May 21;135(21):1829-32.全文 摘要
173. Centers for Disease Control and Prevention. COVID-19: people at increased risk and other people who need to take extra precautions. Mar 2022 [internet publication].全文
174. Svensson P, Hofmann R, Häbel H, et al. Association between cardiometabolic disease and severe COVID-19: a nationwide case-control study of patients requiring invasive mechanical ventilation. BMJ Open. 2021 Feb 17;11(2):e044486.全文 摘要
175. Longmore DK, Miller JE, Bekkering S, et al. Diabetes and overweight/obesity are independent, nonadditive risk factors for in-hospital severity of COVID-19: an international, multicenter retrospective meta-analysis. Diabetes Care. 2021 Jun;44(6):1281-90.全文 摘要
176. Public Health England. Excess weight and COVID-19: insights from new evidence. Jul 2020 [internet publication].全文
177. Hendren NS, de Lemos JA, Ayers C, et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 cardiovascular disease registry. Circulation. 2021 Jan 12;143(2):135-44.全文 摘要
178. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020 Nov;21(11):e13128.全文 摘要
179. Kompaniyets L, Goodman A, Belay B, et al. Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death - United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-61.全文 摘要
180. Arulanandam B, Beladi H, Chakrabarti A. COVID-19 mortality and the overweight: cross-country evidence. Public Health Pract (Oxf). 2021 Nov;2:100179.全文 摘要
181. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-9.全文 摘要
182. Holt H, Talaei M, Greenig M, et al. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). Thorax. 30 Nov 2021 [Epub ahead of print].全文 摘要
183. Mahamat-Saleh Y, Fiolet T, Rebeaud M, et al. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open. 2021 Oct 25;11(10):e052777.全文 摘要
184. Aminian A, Bena J, Pantalone KM, et al. Association of obesity with post-acute sequelae of COVID-19 (PASC). Diabetes Obes Metab. 2021 Sep;23(9):2183-8.全文 摘要
185. Piernas C, Patone M, Astbury NM, et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2022 Aug;10(8):571-80.全文 摘要
186. Gittoes NJ, Criseno S, Appelman-Dijkstra NM, et al. Endocrinology in the time of COVID-19: management of calcium disorders and osteoporosis. Eur J Endocrinol. 2020 Aug;183(2):G57-65.全文 摘要
187. Yu EW, Tsourdi E, Clarke BL, et al. Osteoporosis management in the era of COVID-19. J Bone Miner Res. 2020 Jun;35(6):1009-13.全文 摘要
188. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID‐19 pandemic: version 3. 2021 Feb;73(2):e1-12.全文 摘要
189. Center to Advance Palliative Care. COVID-19 response training. Apr 2020 [internet publication].全文
190. Kumar S, Haqqani H, Wynn G, et al. Position statement on the management of cardiac electrophysiology and cardiac Implantable electronic devices in Australia during the COVID-19 pandemic: a living document. Heart, Lung and Circulation. 2020 Jun 01;29(6):E57-68.全文
191. MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022 Jul;4(7):e490-506.全文 摘要
192. Gelfand JM, Armstrong AW, Bell S, et al. National psoriasis foundation COVID-19 task force guidance statements. Apr 2022 [internet publication].全文
193. International Psoriasis Council. IPC statement on the coronavirus (COVID-19) outbreak. Sep 2020 [internet publication].全文
194. Abhishek A, Boyton RJ, Peckham N, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 2022 Jun 27 [Epub ahead of print].全文 摘要
195. American Society for Hematology. COVID-19 and VTE-anticoagulation: frequently asked questions. Feb 2022 [internet publication].全文
196. European League Against Rheumatism. EULAR guidance for patients COVID-19 outbreak. Apr 2020 [internet publication].全文
197. Arthritis and Musculoskeletal alliance. Principles for COVID-19 vaccination in musculoskeletal and rheumatology for clinicians. Apr 2022 [internet publication].全文
198. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20-May 21, 2020. Emerg Infect Dis. 2020 Oct;26(10):2473-6.全文 摘要
199. Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021 Oct;174(10):1483-7.全文 摘要
200. Verma A, Huffman JE, Gao L, et al. Association of kidney comorbidities and acute kidney failure with unfavorable outcomes after COVID-19 in individuals with the sickle cell trait. JAMA Intern Med. 2022 Aug 1;182(8):796-804.全文 摘要
201. Sickle Cell Disease Association of America. Sickle cell disease and COVID-19: provider advisory. May 2020 [internet publication].全文
202. Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection. JAMA. 2020 Jul 30;324(7):623-4.全文
203. U.S. Food and Drug Administration. Possible false RPR reactivity with BioPlex 2200 Syphilis Total & RPR test kit following a COVID-19 vaccine - letter to clinical laboratory staff and health care providers. Dec 2021 [internet publication].全文
204. Rutherford MA, Scott J, Karabayas M, et al. Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: a binational, registry-based cohort study. Arthritis Rheumatol. 2021 Sep;73(9):1713-9.全文 摘要
205. The Transplantation Society. Guidance on coronavirus for transplant clinicians. Jun 2020 [internet publication].全文
206. American Society for Haematology. COVID-19 and thalassemia: frequently asked questions. Jan 2022 [internet publication].全文
207. Farmakis D, Giakoumis A, Cannon L, et al. COVID-19 and thalassaemia: a position statement of the Thalassaemia International Federation. Eur J Haematol. 2020 Oct;105(4):378-86.全文 摘要
208. American Society for Hematology. COVID-19 and thrombotic thrombocytopenic purpura: frequently asked questions. Apr 2022 [internet publication].全文
209. Wang Q, Guo S, Wei X, et al. Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021). BMJ Open. 2022 Jun 20;12(6):e059396.全文 摘要
210. Dheda D, Perumal T, Moultrie H, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022 Mar 23 [Epub ahead of print].全文 摘要
211. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Jun 2022 [internet publication].全文
212. NHS England. COVID-19: Provision of tuberculosis services update. Feb 2021 [internet publication].全文
213. British Society of Gastroenterology. Expanded consensus advice for the management of IBD during the COVID-19 pandemic. Mar 2021 [internet publication].全文
214. International Uveitis Study Group. Evolving consensus experience of the IUSG-IOIS-FOIS with uveitis in the time of COVID-19 infection. Apr 2020 [internet publication].全文
215. Hung JCH, Li KKW. Implications of COVID-19 for uveitis patients: perspectives from Hong Kong. Eye (Lond). 2020;34(7):1163-64.全文 摘要
216. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-78.全文 摘要
217. Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020 May;115(5):766-73.全文 摘要
内容使用需遵循免责声明